U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C15H23N3O3
Molecular Weight 293.3614
Optical Activity ( + / - )
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of S-40503

SMILES

CN(C)[C@H]1C[C@H](NC2=CC=C(C=C12)[N+]([O-])=O)C(C)(C)CO

InChI

InChIKey=YNYAUBNZRZVNLX-KBPBESRZSA-N
InChI=1S/C15H23N3O3/c1-15(2,9-19)14-8-13(17(3)4)11-7-10(18(20)21)5-6-12(11)16-14/h5-7,13-14,16,19H,8-9H2,1-4H3/t13-,14-/m0/s1

HIDE SMILES / InChI

Approval Year

Name Type Language
S-40503
Common Name English
2-QUINOLINEETHANOL, 4-(DIMETHYLAMINO)-1,2,3,4-TETRAHYDRO-.BETA.,.BETA.-DIMETHYL-6-NITRO-
Systematic Name English
2-(4-(DIMETHYLAMINO)-6-NITRO-1,2,3,4-TETRAHYDROQUINOLIN-2-YL)-2-METHYLPROPAN-1-OL
Systematic Name English
Classification Tree Code System Code
WIKIPEDIA Designer-drugs-S-40503
Created by admin on Sat Dec 16 11:38:07 GMT 2023 , Edited by admin on Sat Dec 16 11:38:07 GMT 2023
Code System Code Type Description
FDA UNII
TBF49WHM83
Created by admin on Sat Dec 16 11:38:07 GMT 2023 , Edited by admin on Sat Dec 16 11:38:07 GMT 2023
PRIMARY
EPA CompTox
DTXSID801027128
Created by admin on Sat Dec 16 11:38:07 GMT 2023 , Edited by admin on Sat Dec 16 11:38:07 GMT 2023
PRIMARY
CAS
404920-28-1
Created by admin on Sat Dec 16 11:38:07 GMT 2023 , Edited by admin on Sat Dec 16 11:38:07 GMT 2023
PRIMARY
CAS
1345011-36-0
Created by admin on Sat Dec 16 11:38:07 GMT 2023 , Edited by admin on Sat Dec 16 11:38:07 GMT 2023
ALTERNATIVE
WIKIPEDIA
S-40503
Created by admin on Sat Dec 16 11:38:07 GMT 2023 , Edited by admin on Sat Dec 16 11:38:07 GMT 2023
PRIMARY S-40503 is an investigational selective androgen receptor modulator (SARM) developed by the Japanese company Kaken Pharmaceuticals, which was developed for the treatment of osteoporosis. SARMs are a new class of drugs which produce tissue-specific anabolic effects in some tissues such as muscle and bone, but without stimulating androgen receptors in other tissues such as in the prostate gland, thus avoiding side effects such as benign prostatic hypertrophy which can occur following treatment with unselective androgens like testosterone or anabolic steroids.
DRUG BANK
DB13938
Created by admin on Sat Dec 16 11:38:07 GMT 2023 , Edited by admin on Sat Dec 16 11:38:07 GMT 2023
PRIMARY
PUBCHEM
57398987
Created by admin on Sat Dec 16 11:38:07 GMT 2023 , Edited by admin on Sat Dec 16 11:38:07 GMT 2023
PRIMARY